PTC Therapeutics | PTCT - Equity Capital And Reserves


PTC Therapeutics reported $-205.31M in Equity Capital and Reserves for its fiscal quarter ending in December of 2025.





Equity Capital And Reserves Change Date
Acadia Pharmaceuticals USD 917.27M 94.89M Sep/2025
Alnylam Pharmaceuticals USD 789.18M 555.28M Dec/2025
Amgen USD 8.66B 961M Dec/2025
BioCryst Pharmaceuticals USD -119.15M 268.74M Dec/2025
Biogen USD 18.21B 573.5M Sep/2025
BioMarin Pharmaceutical USD 6.09B 30.29M Dec/2025
Cytokinetics USD -659.62M 138.5M Dec/2025
Daiichi Sankyo JPY 1.71T 57.86B Dec/2025
Enanta Pharmaceuticals USD 126.59M 61.87M Dec/2025
Esperion Therapeutics USD -301.96M 149.4M Dec/2025
Gilead Sciences USD 22.62B 1.16B Dec/2025
Incyte USD 5.17B 516.28M Dec/2025
Ionis Pharmaceuticals USD 617.97M 13.76M Sep/2025
Ironwood Pharmaceuticals USD -264.16M 44M Sep/2025
Karyopharm Therapeutics USD -292.93M 23.67M Dec/2025
Novartis USD 46.13B 1.38B Dec/2025
Pfizer USD 92.8B 4.11B Sep/2025
PTC Therapeutics USD -205.31M 49.56M Dec/2025
Puma Biotechnology USD 115.27M 10.55M Sep/2025
Roche Holding CHF 33.8B 758M Dec/2025
Sangamo BioSciences USD 19.6M 14.7M Jun/2025
Sarepta Therapeutics USD 1.14B 179.5M Dec/2025
TG Therapeutics USD 648.02M 40.8M Dec/2025
Ultragenyx Pharmaceutical USD 9.16M 142.13M Sep/2025
Vertex Pharmaceuticals USD 18.67B 1.35B Dec/2025
Xencor USD 635.59M 10.27M Dec/2025